Quidel Corporation (QDEL): Price and Financial Metrics
Quidel Corporation (QDEL)
Today's Latest Price: $246.64 USD
Updated Jul 10 4:00pm
Add QDEL to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
QDEL Stock Summary
- With a price/earnings ratio of 117.29, Quidel Corp P/E ratio is greater than that of about 94.62% of stocks in our set with positive earnings.
- Price to trailing twelve month operating cash flow for QDEL is currently 63.64, higher than 95.12% of US stocks with positive operating cash flow.
- With a year-over-year growth in debt of -37.46%, Quidel Corp's debt growth rate surpasses merely 7.54% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Quidel Corp, a group of peers worth examining would be NIU, LOGI, VAR, PAYC, and TECH.
- Visit QDEL's SEC page to see the company's official filings. To visit the company's web site, go to www.quidel.com.
QDEL Stock Price Chart Technical Analysis Charts
QDEL Price/Volume Stats
| Current price | $246.64 | 52-week high | $248.00 |
| Prev. close | $244.96 | 52-week low | $52.49 |
| Day low | $242.02 | Volume | 523,307 |
| Day high | $247.22 | Avg. volume | 825,361 |
| 50-day MA | $186.27 | Dividend yield | N/A |
| 200-day MA | $104.52 | Market Cap | 10.36B |
Quidel Corporation (QDEL) Company Bio
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, womens health, and gastrointestinal diseases. The company was founded in 1979 and is based in San Diego, California.
QDEL Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $246.64 | $412.72 | 74% |
We started the process of determining a valid price forecast for Quidel Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Quidel Corp ranked in the 59th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Quidel Corp ended up being:
- The company's balance sheet shows it gets 99% of its capital from equity, and 1% of its capital from debt. Its equity weight surpasses that of 88.91% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately just 5.46% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- QDEL's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 54.69% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 70% |
| 1% | 72% |
| 2% | 74% |
| 3% | 75% |
| 4% | 77% |
| 5% | 79% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as QDEL, try CBPO, PBH, UTHR, ANTM, and UHS.
Loading social stream, please wait...